Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

Sanofi is proposing a new model for distributing drug discounts under the federal 340B program, according to the Wall Street ...

Sanofi is the third company - along with J&J and Eli Lilly - to attempt to change the way it pays for medicines under the ...

The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income ...

Under Sanofi's new plan, certain hospitals covered by the 340B program would order drugs at full price from a wholesaler. "The changes we are making are consistent with the 340B program's mission ...

In a letter sent to hospitals and clinics on Friday, Sanofi indicated that certain hospitals covered by the 340B Drug Discount Program would receive credits for medicines ordered at full price ...

The federal government created this system in 1992 as part of the 340B program to reduce drug prices. Sanofi’s new plan will allegedly require hospitals to show the details of their pharmacy and ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...